---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269537"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:45:20.190701+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alector Q3 net loss $34.7M; cash $291.1M; selects lead candidates AL137, AL050; RIF 47%

## Summary
- Net loss $34.7M ($0.34/sh) vs $42.2M ($0.43) in Q3 2024; revenue $3.3M, down from $15.3M.
- Cash $291.1M, with $20M ATM proceeds Sep-Oct 2025; runway through 2027.
- Lead candidates selected: AL137 (ABC anti-amyloid beta, IND 2026) and AL050 (ABC GCase, IND 2027).
- Latozinemab Phase 3 INFRONT-3 failed; open-label extension discontinued.
- Implemented ~47% workforce reduction in Oct 2025 to focus on priority programs.

## SEC filing metadata
- accession: 0001193125-25-269537
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000119312525269537/0001193125-25-269537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000119312525269537/alec-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269537
- JSON: https://secwatch.observer/filing/0001193125-25-269537.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.